Physician profile
Alexandra Buford
NPI 1386959500
$698.51
in general payments reported to CMS, 2019-2025
11 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $70.64 · 2023: $92.57 · 2024: $184 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.92 |
| Education | $112.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.55 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $141.86 | 2024-2025 | Veozah |
| Lilly USA, LLC | $76.92 | 2022-2025 | |
| Exact Sciences Corporation | $75.80 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $69.08 | 2025 | |
| Pfizer INC. | $66.03 | 2023-2025 | |
| Amgen INC. | $37.83 | 2024 | Evenity |
| Astrazeneca Pharmaceuticals LP | $28.54 | 2022-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $18.94 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.88 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.